Protein / target
Matrilysin
Protein at a glance
Biological role
Serine-type endopeptidase activity
Strongest disease association
prostate carcinoma
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved · 1 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase
Subcellular location
Domains and Gene Ontology detail (16)Hide
Gene Ontology
- Cextracellular exosome
- Cextracellular matrix
- Cextracellular region
- Cextracellular space
- Fendopeptidase activity
- Fmetalloendopeptidase activity
- Fmetallopeptidase activity
- Fserine-type endopeptidase activity
- Fzinc ion binding
- Pcollagen catabolic process
- Pextracellular matrix disassembly
- Pextracellular matrix organization
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell adhesion
- ·Secreted, extracellular space, extracellular matrix
- ·extracellular matrix
- ·extracellular matrix disassembly
- ·extracellular matrix organization
Proteolysis
- ·endopeptidase activity
- ·metalloendopeptidase activity
- ·metallopeptidase activity
- ·serine-type endopeptidase activity
View underlying pathways (5)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Matrix metalloproteinase 7 inhibitor
Appears in clinical studies involving acne, periodontitis, infection, rosacea
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,135 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 3 total
acne · periodontitis · infection
acne · rosacea · Osteopenia
lung cancer · malignant pancreatic neoplasm · non-small cell lung carcinoma
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Related literature
Papers indexed under “Matrix Metalloproteinase 7” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA207757)
- New publicationGuidelines of care for the management of acne vulgaris.
- Label change
Label change: DOXYCYCLINE (ANDA207757)
- New publicationEffect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial.
- Regulatory approval
Approval: DOXYCYCLINE (ANDA207757)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- New publicationIn vitro and in vivo evaluation of doxycycline-chondroitin sulfate/PCLmicrospheres for intraarticular treatment of osteoarthritis.
- Regulatory approval
Approval: DOXYCYCLINE (ANDA204234)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.